Comfort in UBS commentary, page-5

Thanks Cafa

Given that the SIRFLOX article was highly read only in 1H CY16 I think the majority of sales growth as a result of that is yet to be realised and reported.

I expect the share price will be volatile through the period of the trials reporting but the underlying dose sales to continue to grow steadily regardless.

With 8 month PFS in the liver I feel confident of a good OS result and very confident of a positive OS in at least a subset group.

October is often a volatile month. Between now and the end of this CY I am looking forward to October being over, uncertainty of the US election result being removed, the Sirtex R&D day and probably a raise in US interest rates which long term should strengthen the USD.